BioXcel doses first subjects in Phase 1 pharmacokinetic study of BXCL501
BioXcel Therapeutics announced that the first six subjects have been dosed in the company's Phase 1 pharmacokinetic and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. BTI continues to explore expanding the range of target indications for BXCL501 beyond its current focus areas of acute treatment of agitation in schizophrenia, bipolar disorder and dementia. Treatment of agitation remains a significant global healthcare challenge in patients with drug and alcohol withdrawal, delirium and post-traumatic stress disorder, as the currently available treatment options are suboptimal, invasive, difficult to administer and often pose safety issues.